Background and purpose: Almost 10% of breast and ovarian cancers are familial, and the majority are linked to BRCA1 and BRCA2 germline mutations. Despite uncertainty about the management of female gene carriers, consensus guidelines have been established to assist practitioners and consultees in making health care decisions.
It is estimated that 5% to 10% of all cases of breast and ovarian cancers are inherited in a dominant autosomal fashion, and a large proportion of them may be due to germline mutations of the two major genes, BRCA1 and BRCA2, recently characterized. No medical evidence in terms of benefit has yet been obtained to serve as a basis for the management of women at high risk of cancer for genetic reasons. Guidelines are, however, urgently needed to avert the development of variable medical practice lacking appropriately organized evaluative framework. This report was written to assist practitioners, and hence the consultees, in making decisions about the appropriate health care strategies in the context of a proven or assumed genetic breast/ovarian cancer risk.
The Ad Hoc Committee would first like to point out the great uncertainty and the large number of difficulties potentially associated with this emerging medical practice which focuses on risks rather than on diseases [1] . On the other hand, the best way of dealing with a consultee or assisting in a diagnosis may involve contacting other members of the subject's family. Collaboration of this kind is neither obvious nor easy. In contrast to traditional medicine, where the medical consultation focuses on a single person, this new approach may involve two or more people with conflicting interests about which the physician may be aware but which he/ she cannot resolve alone [2] .
Since it should be borne in mind that the right of individuals to make their own decisions must be given * First published in French [7] . priority, the Ad Hoc Committee feels that it is of the utmost importance to define the process by which information is communicated between practitioners and consultees. Practitioners should ensure that all of the relevant information has been delivered and correctly understood [3] , and that the psychological effects of this information on the subject has been taken into account.
The aim of the present guidelines is not to provide physicians with definitive rules but to outline what seems to be a feasible framework. Indeed, it should be stressed that local social, economic, legal and cultural factors [4] are bound to substantially affect their application [5] .
This report only partly answers the question of what should be done, but focuses rather on the criteria that should be satisfied when proposing and performing medical interventions.
The following four sections will be addressed here: the methodology used; the epidemiological, genetic, clinical, biological, and ethical background; the cancer genetics consultation process; and guidelines for the medical management.
Methodology
In 1995, at the behest of the French National Cancer Center Network (FNCLCC), the National Institute for Health and Medical Research (INSERM) set up an Ad Hoc Committee to analyze the questions arising about the management of the genetic risks associated with breast/ovarian cancer. The FNCLCC covers 20 cancer centers in France with a homogeneous geographical distribution. Every year, about 14,000 new breast carcinomas and 1,000 new ovarian cancer cases, corresponding to almost 55% and 25%, respectively, of all of the cases diagnosed in France, are managed at least partially at these centers. A cancer genetic clinic has been set up at each of these institutes, and a survey showed that they account for almost 80% of the total activity of all cancer genetics consultations recorded in France [6] . Up to 75% of these consultations are likely to be oriented to breast and ovarian cancers.
The Ad Hoc Committee consisted of 14 experts who, after two preparatory working sessions, were designated by INSERM on the basis of their expertise and with a view to the formation of a representative group, using the following criteria: 1) the various specialties involved in the cancer genetic field; 2) memberships in leading scientific societies; 3) their respective places of work; as well as 4) the legal and economic status of the institution where the expert was working (public hospital, fee-paying consultancy, university, etc.). The ratio of women to men was 5 :9, in line with the French medical statistics on the occupational groups present. The process of expert consensus began in June 1995. Eight analytical workshops on specific themes took place between September 1995 and September 1996, at which a systematic analytical review of the international literature was carried out. Three meetings were subsequently held, at which the present guidelines were drawn up. More than 3500 articles selected from various databases, such as Medline, Embase, Biosis and Cancerline, were reviewed. Articles from other sources selected by the experts were consulted, particularly ones regarding the sociological, legal and psychological aspects. On ethical issues, a specific database, that of the INSERM Documentation Center on Ethics, was used. The review of the literature was completed in May 1997. Fifteen additional experts were invited to attend specific workshops, and another five experts who had not participated at any of the workshops then critically analysed the first version of the report. This was summarized at the last meeting, and the final version of the full report has been published [7] .
The present guidelines were written to help those dealing with women who harbor a deleterious mutation involving one of the major predisposing genes, BRCA1 or BRCA2. Since information on carrier status is not always available, and the penetrance [8] or the tumor spectrum may differ from one mutation to another [9, 10] , a probability scale (theoretical range from 0% to 100%) of the risk of developing breast or ovarian cancer was defined.
Using only one interventional threshold defining two categories (intervene versus not) gives rise to some rather sharp distinctions among subjects. For example, if the threshold value is a risk of 50%, a women with a 51% probability of harboring a mutation will be placed in a dramatically different class from one having a 49% risk level. Two thresholds were therefore considered in order to define three categories. These thresholds were intended to assist in determining whether an intervention would be worthwhile. The first is the level above which an intervention can be envisaged, and if the risk/benefit ratio seems to justify it, the intervention can even be recommended in this group. The second threshold is the level below which an intervention can be ruled out. When a woman's score lies between the two thresholds, no definite opinion can be given, and the decision will have to be made by analysis of the details of each situation.
Evaluating a subject's probability level is therefore of great value as a decision-making tool, and it is a twostep process. The first step is to determine a given woman's probability of harboring a deleterious mutation: a level of 100% corresponds to cases where the existence of this mutation has been proven, and the level of 50% corresponds to risks associated with a dominant autosomal disease (as for instance in the case of the daughter of a woman who died at the age of 35 of an ovarian cancer, and whose three sisters had breast cancer with an early onset at the age of 35, 38 and 40 years). These probability levels can be evaluated using either informal procedures, risk tables [11, 12] , or a formal algorithm under assumptions, using a software package with a linkage analysis [13] . The second step consists of multiplying this probability by the expected penetrance of the mutation.
Epidemiological, genetic, clinical, biological, and ethical background
Uncertainty is the hallmark of the cancer genetics field: 1) at the familial level: 'Your mother has a 70% risk of harboring a deleterious mutation'; 2) at the individual level: 'You have a 50% risk of inheriting a mutation existing at your parents' level'; 3) about the tumor spectrum, and the penetrance of the disease: 'With this mutation, you have a 60% to 80% risk of developing breast cancer'; 4) about the curability of the tumor: 'Breast cancer may be curable in 60% to 70% of all such cases, and this may partly depend on the type and the stage of the tumor'; and 5) about the efficacy of preventive care: 'By regularly undergoing mammography you can reduce the mortality rate by 30%'.
Risk is both a formal and a fuzzy concept. It is formal because it can be calculated (with confidence intervals), and fuzzy at the psychological level. Medical staff should pay attention not only to the formal terms in which risk is expressed and communicated but also to how the consultees integrate the information they receive, particularly in the case of probabilistic figures [14] .
Epidemiology and genetic epidemiology
It has been estimated that women with a BRCA1 germline mutation have an 87% lifetime risk of developing breast cancer [15] which will be bilateral in almost half of them [15] , and a 44% to 63% lifetime risk of developing ovarian cancer [15, 16] , whereas women who are BRCA2 germline carriers are thought to have a breast cancer risk similar to that associated with BRCA1 [17] , but a lower risk of ovarian cancer [17] . Nevertheless, recent analyses of specific mutations in specific populations seem to indicate that the cancer incidence rates are much lower than this [8] . As previous results were based on research studies with different modes of sampling and ascertainment [17, 18] , the cumulative risks of cancer may have been overestimated [19] , and the consultees should be informed of this possibility. The wide range evaluated prior to molecular analysis should be given for BRCA1 and BRCA2 mutations combined, which works out from 56% [8] to 87% [15] for breast cancer, and from 16% [8] to 63% [20] for ovarian cancer.
In France, the mortality rate due to breast cancer is about 18 of 100,000 per year [21] , whereas the annual incidence is about 43 of 100,000 [22] . In the case of ovarian cancer, these values are about five of 100,000 and six of 100,000, respectively. As the contribution of BRCA1 and BRCA2 germline mutations to the total number of cases of breast and ovarian cancers is about 5% to 10% [23, 24] , it can be said that every year, per 100,000 women, two to four cases of breast cancer, and 0.4 to 0.8 cases of ovarian cancer are due to BRCAl or BRCA2 mutations. Hence, based on what seem to be reasonable figures of approximately 80% (range 56% [8] to 87% [15] ) and 40% (range 16% [8] to 63% [20] ) of breast and ovarian cancer lifetime risk, respectively, and assuming the mortality rate to be the same as with the sporadic cases [25] , it can be predicted that if no specific interventions are undertaken, about 60% of these cancer-prone women will die of one of these two cancers (according to the most favorable hypothesis, the predicted breast and ovarian mortality rate will still be 33% among women with a germline mutation, and to the worst hypothesis, the rate will be above 80%). These figures can be compared with the approximately 4% for all women with no genetic predisposing risk factors. As hereditary cancer occurs 15 to 20 years earlier in the patients' lifetimes, the burden in terms of years lost in this case is even greater.
The involvement of associated risk factors is a controversial issue with respect to women with a familial cancer risk. Even the hypothesis that a given risk factor may increase or decrease the risk in the same way in a woman regardless of her genetic status should be adopted with great caution [26] , and no major decisions should be taken on the basis of hypotheses of this kind.
Although concrete and steady progress has been made in cancer control, the mortality rate is still of concern. At present no major advances appear to be forthcoming. The management of high-risk women is therefore definitely a priority.
Clinical patterns
It should be stressed that the same clinical picture (phenotype) can be observed in patients with either no germline mutations (phenocopies or sporadic cases) or mutations of different predisposing genes (genetic heterogeneity): BRCAl, BRCA2 or others [27] . Some clinical features may be present, however, which argue in favor of either: 1) a genetic risk, such as the number and the pattern of familial distribution of cases, age at onset, and the bilaterality of cancers [15] ; 2) a BRCAl germline mutation: the occurrence of both breast and ovarian cancers within a family [13, 28] or in the same individual [29] ; and 3) a BRCA2 mutation, e.g., the occurrence of male breast cancer [30] .
Evidence is mounting that hereditary carcinomas have specific morphological patterns, which suggests that the natural history differs from that of sporadic cases [31, 32] . In particular, BRCA1 -associated breast cancers are highly proliferating and poorly differentiated tumors [33] [34] [35] . Surprisingly, despite these elements suggestive of poor prognosis, the overall survival rates among patients with hereditary breast cancer [34, 36, 37] as well as those with inherited ovarian carcinomas [38] are almost equivalent to, or even better than, those of patients with so-called sporadic forms of cancers.
Mutation carriers are liable to have tumors at sites other than the breast and the ovaries. It has been reported that BRCAl mutation carriers have an increasing risk of colorectal cancer, amounting to four times that of the population as a whole [15] . The risk of prostate cancer among men with predisposing mutations {BRCAl and BRCA 2) is probably higher than among the popula-tion at large [8, 15] , and that of pancreatic cancer may be higher in BRCA2 mutation carriers [39] .
Data on risk for cancer localizations other than breast and ovary, however, do not permit statements on their management.
Molecular biology
The BRCA1 and BRCA2 mutations are dispersed over all the coding regions, and only a few recurrent mutations have been described [40, 41] . In contrast to the large number of different mutations observed and recorded in the Bic database [42] , the neo mutation rate seems to be low. In addition, no fast, reliable, simple and cheap molecular biology techniques have thus far been developed [43] . The absence of hot spots has made it difficult to develop any simple mutation search strategies. Progress in this field is needed. The detection rate depends on both the criteria chosen to select the individuals as well as families under study, and on the methods adopted. The currently available mutation search strategies involve a combination of various molecular techniques, in addition to several procedures for selecting families, based either on clinical elements only or associated with linkage analyses (considered the gold standard), and give a mutation detection rate of 16% [29] to 80% [44] , respectively. The majority of deleterious mutations, almost 80%, correspond to frameshift, nonsense, or splice mutations, which predictably lead to truncated BRCA1 and BRCA2 proteins. About specificity, in exon 27 of BRCA2, a variant was recently described which may lead to a truncated protein, which occurs in the population at large and thus seems to correspond to a polymorphism [45] . Missense mutations are rarer, and their biological significance remains to be proven (i.e., whether or not they are associated with an increased risk of cancer), except for that in the ring finger domain of the BRCA1 gene [41] , Observed detection rates, based on the usual criteria such as age at onset and familiy history, appear to be lower than expected [46, 47] .
Molecular biology tools are indispensable for identifying a mutation with reasonable certainty (see above) within a family, and subsequently for checking the genetic status of a member of the family. It seems likely that clarification of genotype-phenotype correlations [9, 48] may one day make it necessary to re-visit the medical guidelines.
Ethical and social issues
Some particulars of the cancer genetics field are worthy of mention. At least half of the consultees are diseasefree [49] and this renders patient-physician relationships different, as the consultation does not focus on specific symptoms. The aim of these consultations is not to diagnose a pathology but to identify a risk, and subsequently a genetic status [2] . The inheritability of this genetic status may be a major issue for the consultee and is sometimes the main reason for the consultation [49] . Drawing up the pedigree is both crucial, as other persons (family members) are involved, and painful, as even consultees with no genetic risk have a family and/ or personal history of cancer. In addition, preventive care will continue for years or even decades. Of the preventive strategies available, prophylactic surgery is mutilating and irreversible. The information communicated may have worrisome psychological and social effects on individuals and their families [50] . There is still a gap between scientific breakthroughs and their usefulness in clinical practice, as well as misperceptions by the public of their usefulness. Finally, there remains the considerable risk that mutation carriers could develop dreadful and frightening diseases.
With such a specific background, what are the main ethical principles to be borne in mind by those responsible for cancer genetics consultations? The first principle is to be beneficial to the consultee. There are three main difficulties to be overcome here: 1) how to define the patient's benefit (life expectancy, quality of life, dignity, etc.), 2) how to measure and balance these concepts, and 3) the fact that what is blieved one day to be best for a consultee may turn out later to have been a mistake. The second principle is respect for individuals' rights and autonomy. Protecting individuals' rights is often presented as the highest aim. In our culture, this is taken to mean that a consultation should necessarily be coercion-free (with no family and/or medical influence) and that subsequently, the consultee should remain in control of any decisions. In France, the following questions are still under debate: are there any limits to people's autonomy? And is it possible for someone in a family of this kind to be influence-free?
The cancer genetics consultation process
The Ad Hoc Committee's opinion is that populationbased or even large-scale BRCA1 mutation screening is not justified for the following two reasons. The social and psychological effects of the testing itself have not yet been established. There is still doubt as to the efficacy of the methods, still at a stage mid-way between research and care [51] , used in the management of cancer-prone individuals. Furthermore, a low prevalence in the population under [46, 47] testing will lead to a very low predictive value and therefore be a waste of resources.
Biological analyses of this kind require at least two consultations with specialists, one before the testing, and the second for disclosure of the results to the consultee. In addition, a follow-up procedure is needed [52] . When women wish to attend a cancer genetics consultation, they should be given access to it in conformity with the existing regulations and legislation. These have been described in detail [53] , but the points most worth mentioning are as follows. It is necessary to provide information prior to the consultation, so that the consultee will know what the purpose is. A written docu-ment should be transmitted to ensure that an informing process has been carried out between the pratictioner and the consultee.
The initial cancer genetics consultation
Women should have access to a well qualified team (see below). The effectiveness of the consultation, in terms of the ratio between the number of women at risk and the number of women consulting, will be greater if referring physicians act as gate keepers, taking into account the family history (i.e., the a priori risk level) [49] . However, the degree of personal concern should be given more weight than the consultee's risk level. A woman who has a low risk of being cancer-prone, but who is worried by her family history should have access to a consultation; whereas in the case of a woman who has a high risk of belonging to a cancer-prone family but is still wavering, the consultation should be postponed, possibly indefinitely. The justification for seeking a consultation should first be checked in order to ensure that the reasons are valid and that the request has been freely and willingly made. The first consultation is a multi-step process covering three important questions: 1) what is the probability that a family (or one of its branches) is cancerprone?; 2) what is the probability that the consultee is a mutation carrier?; 3) how should this person be best advised with a focus on discerning whether or not gene testing is appropriate and desired by the consultee.
Molecular testing
Information delivered prior to molecular testing [54] . Consultees should be informed about the technical limits of the test (see above); about the time required to obtain the results; and about the medical and non-medical consequences of a positive as well as of a negative result, on uncertainties, limits and pitfalls of the screening and preventive strategies and, depending on the local organization (state), on employment and/or insurance discrimination [55] .
Procedure. A further consultation should be arranged before informing the consultee of the results in order to check whether or not she still wants to know them.
Indications. In the case of adult diseases such as breast and ovarian cancers, the opinion of the Ad Hoc Committee is that no testing should be carried out on consultees who are not yet legally of age (18 years old in France). In addition, two factors should then be taken into account: the consultee's willingness, and the prior probability of discovering a mutation. The Ad Hoc Committee feels that a prior probability upward of 25% justifies proposing molecular testing and that a prior probability of 5% or less justifies the decision not to have the test carried out. If laboratory resources are limited, priority should be given to the families with the highest a priori probabilities and/or consultees about whom medical decisions have to be taken, especially when a request for prophylactic surgery has been made.
Follow-up after the consultation
A well-organized follow-up should be carried out within a multidisciplinary team. This team should provide: psychological help [56] for women regardless of whether or not they carry a mutation; an all-inclusive process of evaluation involving a medical, psychological and social appraisal of the consultation and any interventions; and a quality control program should be adopted for each procedure (mammography, surgery, histopathology, molecular genetic testing, etc.).
Legislation and organization
Each state has its own legislation, and the relevant rules should be made known to the profession. The Ad Hoc Committee has pointed out two possible ways of organizing cancer genetics consultations: there can be either a consultation with a practitioner trained in both genetics and oncology, or two consultations, one with a geneticist who evaluates the risk, proposes molecular testing and announces the results, and the other one with an oncologist or other specialist (mainly here a gynecologist) who gives advice about the medical management. Whichever of these methods is chosen, medical decisions should be taken in a multidisciplinary framework including at best the following persons: an oncologist, a geneticist, a molecular biologist, a surgeon, a medical imaging specialist, an endocrinologist and/or a gynecologist, and a clinical psychologist. All of the members who interact with the consultee of the multidisciplinary team should be trained in the medical, psychological and social aspects [57] of cancer genetics, with periodical updating.
Matter of principle
Since decisions have to be made in a context of major uncertainties, several recommendations should be followed: 1) any public statements to the media should be worded with great caution; 2) the key concept is informing the consultee at each stage in the process. It should be noted that face to face interviews may be the best way to give information [58] . Further alternative methods of information disclosure should be tested, taking cultural factors and possible illiteracy into account [59] ; 3) the medical team in charge of these persons should be properly trained and should have acquired relevant experience.
Guidelines to the medical management
In the following part of this text, the Ad Hoc Committee has adopted an individual approach rather than a community approach to public health matters. Whatever medical strategies may be proposed, the key person is always the consultee in the decision-making process. It is the duty of the medical team to deliver relevant information and counseling in line with the recommendations presented here. The main factors to be taken into account are: the age of the woman, and depending the situation, either her probability of being cancerprone or her probability of developing a cancer (see above).
Lack of specific data in particular complex issues such as diet interventions or as hormonal stimulation for infertility may lead to discretionary positions, reflecting medical hypothesis, risk aversion and sociocultural trends.
Two distinct situations will be analyzed: that of disease-free women at risk, and that of women already afflicted by breast or ovarian cancer. Table 1 and Figure 1 )
Disease-free women at risk: Breast cancer prevention strategies (summary in

Hormonal contraception and hormone replacement therapy
Information delivered. The controversies, the advantages and drawbacks of these hormonal treatments should be clearly explained [60] [61] [62] . The lack of certainty as to their effects in cases where there is a hereditary risk should be stressed. Alternative interventions should also be discussed.
Procedure. Neither hormonal contraception nor hormone replacement therapy seem to be contra-indicated for women with a genetic risk of breast/ovarian cancer. Hyperestrogenemia should be avoided however, and the prescription, for a combined agent (estrogen-progestogen), should therefore be written, taking into account both the type of molecule and the dosage.
Indications. The above procedure is applicable whatever the consultee's risk of being cancer-prone may be.
Primary breast cancer prevention
Diet and family planning Although a low-fat or high-fiber diet may decrease the risk of so-called sporadic breast cancer [63] , evidence is still lacking that specific diets are actually necessary [64] . We have neither the relevant evidence, nor the right to recommend specific family planning measures. Consultees should nevertheless be informed about the possibility of having prophylactic ovarian surgery, after 35 or 40 years of age (according to the criteria described below), so that they can take this information into account in planning their families.
Chemoprevention
Information delivered. Tamoxifen may be used in the frame of research protocols [65] , and the patients involved should be given specific information about the ongoing trial and preliminary results (BCPT).
Procedure. A specific design for each type of clinical trial.
Indications. Until definitive data are available [66] , the Ad Hoc Committee has ruled out the preventive use of tamoxifen by premenopausal women because it entails a risk of ovarian hyperstimulation [67] . In the case of menopausal women, its use can be envisaged but the Committee has doubts as to whether prescribing tamoxifen is appropriate here, since 50% of the high-risk women in this age group have already developed breast cancer. Data on molecules other than tamoxifen do not allow statements on their utilization. 
Breast cancer screening (without imaging)
Breast self-examination Information delivered. There is some doubt as to whether this procedure is effective [68, 69] , and it may also induce anxiety in some women [70] .
Procedure. Systematic breast self-examination.
Indications. Systematic breast self-examination is not recommended if viewed as a mandatory procedure, since there exists some doubt as to whether it is effective and because it is not desirable to shift the responsibility for screening onto the women themselves. However, women who do wish to carry out self-examination should be given technical training under professional guidance from the age of 20 years onwards.
Clinician breast examination Information delivered. Few side effects are liable to arise as the result of breast examination by a well-trained physician.
Procedure. Women at risk should be examined clinically by a physician two or three times a year. A careful examination should be carried out systematically at each consultation during pregnancy and during the postpartum period. These women should be told to note any unusual symptoms, whether or not they have recently undergone mammographic screening.
Indications. This procedure is recommended from the age of 20 years onwards for women with a risk of 20% or more of developing a breast cancer, but should not be used by women with a risk of less than 10%. For the latter women, standard procedures should be recommended depending on their age [71] .
Tumor markers
The use of tumor markers should be restricted to clinical trials.
Breast cancer screening by imaging
Mammography
Information delivered. Although mammographic screening is assumed to be an effective means of reducing the mortality due to breast cancer in population-based studies, no data on cancer-prone women are yet available [72] , nor about the onset age of screening. To be effective, mammographic screening should be undergone on a regular basis. This option seems to be recommendable despite the hypothesis that cancer may be induced by radiation, particularly in genetically predisposed women, as mentioned by the authors of some theoretical studies [73] . Since mammography screening is associated with a major increase in the diagnosis of ductal carcinoma in situ, consultees should be given a detailed explanation about the unknowns surrounding the natural history of these lesions and their appropriate treatment.
Procedure. Mammographic screening should be carried out annually along with a clinical examination. Mammography should be performed prior to planned pregnancy and during the first six months after giving birth. The screening should be continued as long as the person's life expectancy makes it worthwhile. Comparative analysis with the previous mammograms should be performed. Two-view (cranio-caudal and medio-lateral oblique) mammographic screening [74] should be performed. The interpretation should be made immediately in order to determine whether an additional view or ultrasonography may be required. Two independent interpretations of the mammograms [75] are required. Mammograms should be performed at centers with considerable experience and with regularly maintained equipment fulfilling quality control standards. When an abnormality is detected, the decision to perform a biopsy should be taken under the collective responsibility of the members of the multidisciplinary staff.
Indications. From 30 years of age or earlier under specific circumstances, depending on the family history (very early onset breast cancer), and/or the presence of individual symptoms. This procedure is recommended for women with a 20% risk or more of developing a breast cancer, but should not be used on women with a risk of less than 10%. With the latter women, population-based recommendations should be applied depending on their age.
Magnetic resonance imagery (MRI)
MRI should never be used alone for screening purposes, and should be evaluated in clinical trials [76] .
Prophylactic surgery on patients with a high breast cancer risk
Prophylactic surgery is in fact a mutilation. This procedure should be envisaged only on medical grounds. The patient's agreement is necessary but is not a sufficiently strong reason for operating. Nevertheless, in situations where no chemopreventive procedures are adopted, using only screening strategies means allowing about 80% of the women screened to develop a breast cancer, and almost 20% of them to die of cancer. This figure takes into account the 30% decrease in the mortality which can be expected to occur as the result of mammographic screening [77] . Although prophylactic mastectomy is never recommended, it may therefore sometimes be envisaged.
Information delivered. Consultees should be informed that prophylactic surgery will not guarantee complete protection [78, 79] , and about the nature and the rates of the possible side effects (including sexual and psychological ones), disadvantages and complications associated with such a procedure, as well as about the efficacy of alternative options (screening and chemoprevention if available).
Procedure. If prophylactic surgery is envisaged, all of the following criteria must be fulfilled: 1) this must be a multidisciplinary decision; 2) the patient's life expectancy must not be significantly reduced due to the presence of another pathology; 3) a consultation with a psychologist belonging to the multidisciplinary team should be proposed prior to the surgery, because of the psychological problems liable to ensue. This consultation is particularly necessary when the probability of harboring a deleterious mutation is not very high; 4) a six-month period of reflection is necessary before proceeding with the operation; 5) attention must be paid to the specific techniques: a total bilateral mastectomy is required, as well as a careful histological examination to rule out the presence of microscopic invasive cancer; 6) immediate high quality reconstruction should be proposed with information about its risks; 7) the National Agency for Medical Evaluation guidelines on mammary implants [80] should be followed, and other recommendations may be taken into account, depending on the country where the surgery is performed; and 8) the patient should be given the appropriate psychological follow-up.
Indications. The Ad Hoc Committee is strongly opposed to the use of prophylactic mastectomy for women under 30 years of age, as the risk of breast cancer below this age does not seem to be high enough to warrant prophylactic surgery. Mastectomy may be envisaged for women with a lifetime risk of more than 60% of developing breast cancer, but should not be performed on women with a lifetime risk of breast cancer of less than 20%.
Disease-free women at risk: Ovarian cancer prevention strategies (summary in Table 2 and Figure 1) 
Ovarian stimulation
Information delivered. Ovarian stimulation may increase the risk of ovarian cancer, but no data are available on this point as far as cancer-prone women are concerned.
Procedure. In cancer-prone women who are being treated for infertility, it might be prudent to limit the attempts at ovarian stimulation.
Indications. The above limitation seems to be reasonable when the risk of being cancer-prone is more than 25%.
Hereditary ovarian cancer screening strategies
Clinical examination, and ultrasonography Information delivered. The efficacy of these methods is unknown and may be low, but in any case, it can be expected to have few direct negative side effects.
Procedure. Two pelvic examinations per year are recommended. A yearly transvaginal ultrasound in addition to a color flow Doppler may be carried out at the beginning of the menstrual cycle on premenopausal women.
Indications. This procedure is appropriate for women from the age of 35 years onwards with a 20% risk or more of harboring a deleterious mutation, but should not be used on women with a risk level of less than 5%. In the latter case, systematic screening is not advisable [81] .
Tumor markers
The use of tumor markers such as Cal25 should be restricted to clinical trials.
Prophylactic surgery on patients with a high risk of ovarian cancer
This procedure is in fact a mutilation. This type of surgery should be envisaged for medical reasons only, and the patient's agreement is necessary but does not constitute grounds for performing the operation.
Information delivered. Patients should be informed that the failure rate of prophylactic oophorectomy is not negligible [82] , and about the nature and the rate of the possible side effects and complications (including sexual and psychological ones), as well as about the value of the only other available option (screening).
Procedure. If prophylactic surgery is envisaged, all of the following criteria must be fulfilled: 1) this must be a muldisciplinary decision; 2) the patient's life expectancy must not be significantly reduced for other reasons; 3) a consultation with a psychologist belonging to the multidisciplinary team should be proposed because of the psychological problems liable to ensue. This consultation is particularly necessary when the probability of harboring a deleterious mutation is not very high; 4) a three-month period of reflection is necessary before the surgery is performed; the choice of a shorter delay than that of mastectomy is based on a better acceptability of prophylactic oophorectomy [83] ; 5) attention should be paid to several technical specificities: 5a) the laparoscopic procedure should be used [84] if there are no contra-indications; 5b) it is necessary to proceed first to a complete examination of the abdominal cavity, comprising a total greater omentum exploration: any spontaneous exudate present in the Douglas cavity should be collected for analysis, and an endoscopic examination should be performed on both ovaries; 5c) to remove both annexa as completely as possible so as to ensure that no residual tissue remains; 5d) extraction should be performed using an endoscopic bag so that no contact occurs between the ovary and the abdominal wall; 5e) careful histological examination should be performed to ensure that no microscopic invasive neoplasms are present [85] ; 6) patients should be given appropriate psychological follow-up, and should undergo evaluative procedures; and 7) a hormone replacement therapy should be proposed, under the conditions listed above.
Indications. The Ad Hoc Committee is strongly opposed to the use of prophylactic oophorectomy on women under 35 years of age as well as on childless women under the age of 40 years unless the uterus has to be removed for other reasons. This procedure seems to be appropriate in the case of women with at least a 20% lifetime risk of contracting ovarian cancer, and in the case of clinical evidence or molecular data indicating that the tumor spectrum in the family under study includes ovarian carcinoma. For women in whom the estimated risk is more than 40% (i.e., when a woman is known to carry a high penetrance deleterious mutation), then prophylactic surgery is actually recommended. Prophylactic surgery should not be performed on women with a lifetime risk of less than 5% of having ovarian cancer.
Women with breast cancer
Surgery
Surgery is the main treatment, but there are too few data available to be able to define exactly the line between the indications for conservative surgery and mastectomy [35, 86, 87] . Mutation carriers may however be the most suitable candidates for mastectomy. Decisions should take into account the classical risk factors responsible for local failure and the risk of having a second ipsilateral breast cancer due to the genetic defect. Prophylactic oophorectomy can be recommended in line with the criteria described above if breast cancer with a favorable prognosis is present.
Other treatments
No proposals were put forward in connection with the other procedures currently in use: radiotherapy, chemotherapy, and hormone therapy.
Follow-up
Screening procedures should be carried out on the contralateral breast under the same conditions as those described for disease-free women with a high genetic risk. Contralateral prophylactic surgery should be envisaged only if a mastectomy has been performed previously in the case of breast cancer.
Women with ovarian cancer
No proposals were put forward regarding the medical management of women with ovarian cancer. 
Minimum appropriate care a matter of principle
Although no scientific evidence is as yet available concerning the validity of the medical care management strategies being used, the Ad Hoc Committee feels that a specific management approach is indispensable. The minimum acceptable program agreed upon was as follows : 1) providing regular clinical medical follow up; 2) providing psychological guidance; 3) providing mammographic screening.
The Ad Hoc Committee advocates the use of properly defined and evaluated procedures, and participation in clinical trials.
These guidelines are the conclusions of the full-scale INSERM-FNCLCC report [7] .
